Mpox vaccine trial for frontline workers shows promise in High-Risk region
NCT ID NCT02977715
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tested the JYNNEOS smallpox vaccine in 1,600 healthcare workers in the Democratic Republic of the Congo who are at high risk of catching mpox. The goal was to see if the vaccine can prevent mpox infection and is safe to use. Participants received the vaccine and were monitored for infections, exposure, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tshuapa site
Boende, Tshuapa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.